US EPA

2306601 

Journal Article 

Neonatal exposure to Thimerosal from vaccines and child development in the first 3 years of life 

Mrozek-Budzyn, D; Majewska, R; Kieltyka, A; Augustyniak, M 

2012 

1 

Neurotoxicology and Teratology
ISSN: 0892-0362
EISSN: 1872-9738 

34 

6 

592-597 

English 

23069197 

10.1016/j.ntt.2012.10.001 

WOS:000312518600007 

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868225279&doi=10.1016%2fj.ntt.2012.10.001&partnerID=40&md5=3532d459dec5ed0d7e3a9219043074e7
Exit
 

BACKGROUND: Despite the common use of Thimerosal as a preservative in childhood vaccines since the 1930s, there are not many studies on ethylmercury toxicokinetics and toxicodynamics in infants. The knowledge of ethylmercury's potential adverse effects is derived mostly from parallel methylmercury research or from animal and theoretical models.

AIM OF THE STUDY: This study was designed to examine the relationship between neonatal exposure to Thimerosal-containing vaccine (TCV) and child development.

MATERIAL AND METHODS: The study sample consisted of 196 infants born between January 2001 and March 2003 to mothers attending ambulatory prenatal clinics in the first and second trimesters of pregnancy in Krakow. Vaccination history (date and the type of the vaccine) was extracted from physicians' records. Child development was assessed using the Bayley Scales of Infant Development (BSID-II) measured in one-year intervals over 3years. General Linear Model (GLM) and Generalized Estimating Equation (GEE) models adjusted for potential confounders were used to assess the association.

RESULTS: An adverse effect of neonatal TCV exposure was observed for the psychomotor development index (PDI) only in the 12th and 24th months of life (β=-6.44, p<0.001 and β=-5.89, p<0.001). No significant effect of neonatal TCV exposure was found in the 36th month. The overall deficit in the PDI attributable to neonatal TCV exposure measured over the course of the three-year follow-up (GEE) was significantly higher in TCV group (β=-4.42, p=0.001). MDI scores did not show the adverse association with neonatal TCV exposure. 

Thimerosal-containing vaccine; Neonatal exposure; Child neurodevelopment